Search clinical trials for: Calcimimetic Agents

Total 188155 results

Astellas Pharma Inc

Completed

Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis

Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy | Pharmacodynamics of ASP7991 | Pharmacokinetics of ASP7991

Japan
Astellas Pharma Inc

Completed

Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects

Healthy | Pharmacokinetics of ASP7991

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers

Healthy | Pharmacokinetics of ASP7991

Japan
Prof. Dominique de Quervain, MD
Clinical Trial Unit, University Hospital Basel, Switzerland

Completed

Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects (Mira-Basel)

Memory Functions

Switzerland
Amgen

Completed

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Chronic Kidney Disease | Secondary Hyperparathyroidism | Kidney Disease
Amgen

Completed

PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice

Hyperparathyroidism, Primary
Amgen

Completed

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease
Children's Mercy Hospital Kansas City

Completed

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

Hypophosphatemic Rickets, X-Linked Dominant

United States
Chinese University of Hong Kong

Completed

Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism

Hyperparathyroidism | Arterial Stiffness

Hong Kong
Seoul National University Hospital
Kyowa Hakko Kirin Pharma, Inc.; Jeil-Kirin Pharmaceutical Inc.

Completed

Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493

Healthy

Korea, Republic of
Shanghai Hengrui Pharmaceutical Co., Ltd.

Active, not recruiting

A Study of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
Kyowa Kirin Co., Ltd.

Completed

An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Primary Hyperparathyroidism | Parathyroid Carcinoma | Hypercalcemia

Japan
Amgen

Completed

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Hyperparathyroidism, Primary
Amgen

Completed

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

Hyperparathyroidism, Primary
Amgen

Completed

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
Children's Mercy Hospital Kansas City

Withdrawn

Calcimimetics in Hypophosphatemic Rickets (CHR)

Familial Hypophosphatemic Rickets

United States
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

End Stage Renal Disease | Secondary Hyperparathyroidism
Tufts University

Completed

The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects

Healthy

United States
Montefiore Medical Center

Terminated

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Secondary Hyperparathyroidism | Hypercalcemia

United States
Papageorgiou General Hospital

Terminated

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Secondary Hyperparathyroidism

Greece
Laval University
Amgen

Completed

Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients (ECIRA)

Chronic Kidney Disease

Canada
Amgen

Completed

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Nephrology
Tanta University

Completed

Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis

Drug Effect

Egypt
Amgen

Completed

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (EVOLVE)

Chronic Kidney Disease | Secondary Hyperparathyroidism
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.

Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Secondary Hyperparathyroidism

China, Hong Kong, Korea, Republic of, Taiwan
Josep M Cruzado

Completed

Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

Secondary Hyperparathyroidism

Spain
Seoul National University Hospital
Jeil-Kirin Pharmaceutical Inc.

Completed

Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level (CUPID)

Secondary Hyperparathyroidism

Korea, Republic of
Kyowa Kirin China Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT (ACTIVE)

Hyperparathyroidism; Secondary, Renal

China
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Secondary Hyperparathyroidism

Japan
Amgen

Completed

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Hyperparathyroidism | End Stage Renal Disease | Chronic Kidney Disease | Kidney Transplantation | Chronic Renal Failure | Hypophosphatemia | Kidney Disease | Chronic Allograft Nephropathy | Disordered Mineral Metabolism | Post Renal Transplantation

United States, Canada, France, Italy, Belgium, Switzerland, Spain, Australia, Germany, Austria, Poland
Amgen

Completed

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Hyperparathyroidism | Parathyroid Neoplasms
Amgen

Completed

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

Chronic Kidney Disease | Secondary Hyperparathyroidism | Hyperparathyroidism, Secondary

United States, Germany, United Kingdom
Amgen

Completed

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Secondary Hyperparathyroidism | Chronic Renal Insufficiency
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

A Research Study for Patients With End-Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects

Hyperparathyroidism
Hartmut Malluche, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Wright...

Completed

Renal Osteodystrophy: An Individual Management Approach

Kidney Failure, Chronic

United States
Amgen

Completed

12-month Study of AMG 073 in Renal Osteodystrophy

Renal Osteodystrophy
Amgen

Completed

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Anemia | Secondary Hyperparathyroidism
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Istituto Auxologico Italiano

Completed

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism (CA-PHP)

Hyperparathyroidism, Primary | Osteoporosis

Italy
Centre Hospitalier Universitaire Vaudois
Swiss National Science Foundation

Completed

Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System

Relationship Between Calcimimetic and the RAAS

Switzerland
Amgen

Completed

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Secondary Hyperparathyroidism, Chronic Kidney Disease

United States, Czechia, Germany, France, Hungary, Greece, Belgium, Italy, Poland, Russian Federation, Ukraine
University Hospital, Rouen
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Evaluation of a Cincalcet Suppression Test

Parathyroid Hormone Suppression Test With Cinacalcet

France
The University of Hong Kong

Completed

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients (PROCEED)

Vascular Diseases | Secondary Hyperparathyroidism | Kidney Failure

Hong Kong
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Trial of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China

Search clinical trials for: Calcimimetic Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations